Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice

Nature Communications

Volumn 8, Issue , 2017, Pages

  Tasfaout, Hichem ^a,b,c   Buono, Suzie ^a,b,c   Guo, Shuling ^d   Kretz, Christine ^a,b,c   Messaddeq, Nadia ^a,b   Booten, Sheri ^d   Greenlee, Sarah ^d   Monia, Brett P ^d   Cowling, Belinda S ^a,b,c   Laporte, Jocelyn ^a,b,c  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDROPYRIDINE RECEPTOR; ALANINE AMINOTRANSFERASE; ANTISENSE OLIGONUCLEOTIDE; ASPARTATE AMINOTRANSFERASE; CALCIUM CHANNEL; DYNAMIN II; MYOTUBULARIN 1; PROTEIN; RYANODINE RECEPTOR 1; UNCLASSIFIED DRUG; DNM2 PROTEIN, MOUSE; MYOTUBULARIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE;

DISEASE; GENETIC ANALYSIS; MUSCLE; MUTATION; PATHOLOGY; PROTEIN; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRONUCLEAR MYOPATHY; CONTROLLED STUDY; DOWN REGULATION; DRUG DELIVERY SYSTEM; GENE EXPRESSION; MALE; MOUSE; MUSCLE WEAKNESS; NONHUMAN; PHENOTYPE; PROTEIN LOCALIZATION; ANIMAL; DISEASE MODEL; FEMALE; GENETIC RECOMBINATION; GENETICS; KIDNEY; KNOCKOUT MOUSE; LIVER; METABOLISM; MUSCLE CONTRACTION; MUTATION; MYOPATHY; SKELETAL MUSCLE;

MUS;

ANIMALS; DISEASE MODELS, ANIMAL; DYNAMIN II; FEMALE; KIDNEY; LIVER; MALE; MICE; MICE, KNOCKOUT; MUSCLE CONTRACTION; MUSCLE, SKELETAL; MUTATION; MYOPATHIES, STRUCTURAL, CONGENITAL; OLIGONUCLEOTIDES, ANTISENSE; PHENOTYPE; PROTEIN TYROSINE PHOSPHATASES, NON-RECEPTOR; RECOMBINATION, GENETIC;

EID: 85020388839     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15661     Document Type: Article

References (30)

1. Arechavala-Gomeza, V., et al. Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: Progress and challenges. Curr. Gene Ther. 12, 152-160 (2012).
2. Benchaouir, R., et al. Gene and splicing therapies for neuromuscular diseases. Front. Biosci. (Landmark Ed.) 20, 1190-1233 (2015).
3. Wheeler, T. M., et al. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488, 111-115 (2012).
4. Finkel, R. S., et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study. Lancet 388, 3017-3026 (2016).
5. Ravenscroft, G., et al. Pathophysiological concepts in the congenital myopathies: Blurring the boundaries, sharpening the focus. Brain 138, 246-268 (2015).
6. Jungbluth, H., et al. Centronuclear (myotubular) myopathy. Orphanet J. Rare Dis. 3, 26 (2008).
7. Spiro, A. J., et al. Myotubular myopathy. Persistence of fetal muscle in an adolescent boy. Arch. Neurol. 14, 1-14 (1966).
8. Laporte, J., et al. A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat. Genet. 13, 175-182 (1996).
9. Cowling, B. S., et al. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy. J. Clin. Invest. 124, 1350-1363 (2014).
10. Cowling, B. S., et al. Increased expression of wild-type or a centronuclear myopathy mutant of dynamin 2 in skeletal muscle of adult mice leads to structural defects and muscle weakness. Am. J. Pathol. 178, 2224-2235 (2011).
11. Liu, N., et al. Mice lacking microRNA 133a develop dynamin 2-dependent centronuclear myopathy. J. Clin. Invest. 121, 3258-3268 (2011).
12. Bitoun, M., et al. Mutations in dynamin 2 cause dominant centronuclear myopathy. Nat. Genet. 37, 1207-1209 (2005).
13. Wang, L., et al. Dynamin 2 mutants linked to centronuclear myopathies form abnormally stable polymers. J. Biol. Chem. 285, 22753-22757 (2010).
14. Kenniston, J. A., et al. Dynamin GTPase regulation is altered by PH domain mutations found in centronuclear myopathy patients. EMBO J. 29, 3054-3067 (2010).
15. Seth, P. P., et al. Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs. Nucleic Acids Symp. Ser. (Oxf.) 52, 553-554 (2008).
16. Pallan, P. S., et al. Structure and nuclease resistance of 20, 40-constrained 20-Omethoxyethyl (cMOE) and 20-O-ethyl (cEt) modified DNAs. Chem. Commun. 48, 8195-8197 (2012).
17. Kurreck, J., et al. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 30, 1911-1918 (2002).
18. Seth, P. P., et al. Short antisense oligonucleotides with novel 20-40 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. J. Med. Chem. 52, 10-13 (2009).
19. Buj-Bello, A., et al. The lipid phosphatase myotubularin is essential for skeletal muscle maintenance but not for myogenesis in mice. Proc. Natl Acad. Sci. USA 99, 15060-15065 (2002).
20. Amoasii, L., et al. Phosphatase-dead myotubularin ameliorates X-linked centronuclear myopathy phenotypes in mice. PLoS Genet. 8, e1002965 (2012).
21. Romero, N. B., et al. Centronuclear myopathies: A widening concept. Neuromuscul. Disord. 20, 223-228 (2010).
22. Al-Qusairi, L., et al. T-tubule disorganization and defective excitationcontraction coupling in muscle fibers lacking myotubularin lipid phosphatase. Proc. Natl Acad. Sci. USA 106, 18763-18768 (2009).
23. Toussaint, A., et al. Defects in amphiphysin 2 (BIN1) and triads in several forms of centronuclear myopathies. Acta Neuropathol. 121, 253-266 (2011).
24. Swayze, E. E., et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35, 687-700 (2007).
25. Burdick, A. D., et al. Sequence motifs associated with hepatotoxicity of locked nucleic acid-modified antisense oligonucleotides. Nucleic Acids Res. 42, 4882-4891 (2014).
26. Van Poelgeest, E. P., et al. Acute kidney injury during therapy with an antisense oligonucleotide directed against PCSK9. Am. J. Kidney Dis. 62, 796-800 (2013).
27. Herrington, W. G., et al. Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma. Am. J. Kidney Dis. 57, 300-303 (2011).
28. Robb, S. A., et al. Impaired neuromuscular transmission and response to acetylcholinesterase inhibitors in centronuclear myopathies. Neuromuscul. Disord. 21, 379-386 (2011).
29. Dowling, J. J., et al. Myotubular myopathy and the neuromuscular junction: A novel therapeutic approach from mouse models. Dis. Model. Mech. 5, 852-859 (2012).
30. Durieux, A. C., et al. Dynamin 2 and human diseases. J. Mol. Med. 88, 339-350 (2010).